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Tumor Vasculature Changes Before or During Treatment to Predict Response to Systemic
Therapy
A diagnosis of non-small cell lung cancer (NSCLC) carries a grim prognosis, with 5-year survival
rates of 25%. 25-30% of NSCLC patients have brain metastases at initial presentation, which
carries an even worse prognosis. New systemic therapies such as targeted-therapies and
immuno-therapies have potential to provide better outcomes, but are not without challenges.
First, efficacy is limited to a subset of patients. Second, the blood-brain barrier limits penetration,
which varies among patients. Third, toxicities can be considerable. Current practice involves
waiting 3-6 months to follow-up and assess tumor response; however, by then, it is later than
ideal to try other therapies, and too late to limit toxicity. Establishing a non-invasive early
predictor of response will accelerate the use of new promising agents and could improve tumor
response and outcomes.
Pre-clinical studies demonstrate changes in tumor vasculature hours after treatment are
predictive of long-term treatment response. The aim of this study is to use dynamic-contrast
enhanced magnetic resonance imaging (DCE-MRI) to evaluate both pre-treatment and
post-treatment vascular measures (vascular volume, vascular permeability, interstitial tumor
pressure) as predictors of long-term response.
This exploratory clinical study will enroll 20 patients to complete 3 DCE-MRI studies. The
response variables will be modeled against the vascular measures at three timepoints
(pre-treatment, immediate post-treatment, and standard follow-up interval (6-8 weeks)) to
assess the predictive ability of tumor vascular characteristics on survival, tumor progression,
and imaging response. The data acquired in this study will be used in planning larger and more
comprehensive trials in the future.

